In patients with advanced non-small cell lung cancer (NSCLC) receiving first-line programmed cell death protein 1 (PD1) therapy, pretreatment total metabolic tumor volume (TMTV) and mean standardized uptake value (SUVmean) are predictive of better tumor responses, and high TMTV is significantly associated with poor overall survival (OS) (8). Here, PDCD1 is linked to neoplasm.